Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The Download: a Nobel winner on AI, and the case for fixing everything

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: a Nobel winner on AI, and the case for fixing everything Date: 2026-05-12 12:10 Source: https://www.technologyreview.com/2026/05/12/1137103/the-download-nobel-winner-ai-maintenance-of-everything/ <p><em>This is today’s edition of </em><a href="https://forms.techn…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Attempts to remove Sam Altman from OpenAI were amateurish

    60% confidence

  • Maintainers haven't gotten the laurels they deserve

    60% confidence

  • Maintenance is a 'civilizational' act; taking responsibility for maintaining something — whether a motorcycle, a monument, or the planet — can be radical

    60% confidence

  • AI would give only a small boost to US productivity and would not eliminate the need for human work

    60% confidence

  • Sam Altman has a pattern of lying; Sutskever spent a year gathering proof of Altman's dishonesty

    60% confidence

  • Stewart Brand's vision of maintenance often feels solitary: profound, but more about personal fulfillment than tending to a shared world or making it better

    60% confidence

  • Elon Musk's hypocrisy over OpenAI becoming a for-profit company will undermine his courtroom battle with Sam Altman

    60% confidence

  • Two years after his cautious AI predictions, the data is still largely on his side despite significant technological advancement

    60% confidence

  • Daybreak will continuously secure software

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com